<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111091">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02087865</url>
  </required_header>
  <id_info>
    <org_study_id>NIH AG022304</org_study_id>
    <nct_id>NCT02087865</nct_id>
  </id_info>
  <brief_title>Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease</brief_title>
  <official_title>Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 24-week study will examine the sensitivity of functional MRI to detect brain changes
      caused by donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk
      for Alzheimer's Disease. Participants with a family history of Alzheimer's Disease will be
      eligible for this study. Participants without a family history of AD will also be enrolled
      to serve as a control group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Change in BOLD response during functional magnetic resonance imaging</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline to 6 month follow-up fMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological testing scores</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in neuropsychological testing scores from baseline to 6 month follow-up visit</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Genetic Risk for Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Donepezil HCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants without a family history of AD will undergo the study evaluations but will not receive any study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil HCL</intervention_name>
    <arm_group_label>Donepezil HCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal general cognitive function

          -  High Risk Group Only: Family history (1st degree relative) of AD

          -  Low Risk Group Only: No family history (1st or 2nd degree relative) of AD

          -  Visual and auditory acuity adequate for neuropsychological testing

        Exclusion Criteria:

          -  Current or past history of

          -  neurological illnesses/conditions

          -  head trauma with significant loss of consciousness

          -  medical illnesses/conditions that may affect brain function

          -  severe psychiatric disorder

          -  substance abuse

          -  unstable or severe cardiovascular disease or asthmatic condition

          -  history of stroke or transient ischemic attack
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen M Rao, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lyla Mourany, M.S.</last_name>
    <phone>216-636-5522</phone>
    <email>mouranl@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic Center for Brain Health</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen M Rao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
